View Post

Researchers develop mechanism that predicts severity of aggressive form of breast cancer

In In The News by Barbara Jacoby

By: Huntsman Cancer Institute From: medicalxpress.com Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer center for the Mountain West, have made a significant breakthrough in predicting the prognosis of triple-negative breast cancer (TNBC), a particularly aggressive disease. Their research, published in JCO Precision Oncology as part of the TOWARDS study, has …

View Post

Chemical screen identifies PRMT5 as therapeutic target for paclitaxel-resistant triple-negative breast cancer

In In The News by Barbara Jacoby

By: Liu Jia, Chinese Academy of Sciences From: medicalxpress.com In a study published in Cell Chemical Biology, a research team led by Prof. Tan Weihong and Prof. Wu Qin from the Hangzhou Institute of Medical of the Chinese Academy of Sciences has identified protein arginine methyltransferases (PRMTs), crucial regulators of RNA splicing and chromatin stability, as a new therapeutic target …

View Post

Researchers mark milestone in progress toward investigational new drug for triple-negative breast cancer

In In The News by Barbara Jacoby

By: Leslie Cantu, Medical University of South Carolina From: medicalxpress.com A new compound developed by researchers at MUSC Hollings Cancer Center shows promise in overcoming chemotherapy resistance in triple-negative breast cancer—and could potentially be applied to fibrotic conditions like liver fibrosis or pulmonary fibrosis. At the center of this work is preventing the protein lysyl oxidase, or LOX, from going …

View Post

High insulin levels contribute to worse outcomes for Black women with aggressive form of breast cancer, research finds

In In The News by Barbara Jacoby

Source: The Endocrine Society From: medicalxpress.com High insulin levels contribute to worse outcomes for Black women compared to white women who have an aggressive form of breast cancer called triple-negative breast cancer, according to a study presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. Triple-negative breast cancer accounts for about 10–15% of all breast cancers. The …

View Post

Soft tumor environments prime cancer cells for survival during metastasis

In In The News by Barbara Jacoby

Source: Garvan Institute of Medical Research From: news-medical.net Researchers have discovered how the mechanical properties of tumors can prime cancer cells to better survive their spread to other organs. A metabolic ‘survival switch’ controlled by the stiffness of triple-negative breast tumors can significantly influence how successfully their cancerous cells spread to other organs, according to new findings from the Garvan …

View Post

Two-Drug Combo Shows Promise as Treatment for Aggressive Form of Breast Cancer

In In The News by Barbara Jacoby

By: University of Colorado Cancer Center From: cancerhealth.com University of Colorado cancer researchers explore ways to overcome resistance to a standard treatment for triple-negative breast cancer Research led by University of Colorado Cancer Center members points to a combination of drugs as a potential treatment option for a type of aggressive breast cancer. Todd Pitts, PhD, and Jennifer Diamond, MD, …

View Post

What Sets Triple-Negative Breast Cancer Apart?

In In The News by Barbara Jacoby

By: Steve Blanchard From: endeavor.moffitt.org Triple-negative breast cancer is one of the most aggressive forms of breast cancer, but many patients who learn of their diagnosis may not understand what the term means. This type of breast cancer lacks the three most common types of receptors that fuel breast cancer growth, according to Moffitt Cancer Center breast radiologist Dr. Shannon …

View Post

Pembrolizumab regimen confers ‘durable and robust’ benefit in triple-negative breast cancer

In In The News by Barbara Jacoby

By: Mark Leiser From: healio.com Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting provided a durable EFS benefit for patients with early-stage triple-negative breast cancer, according to study results. The benefit persisted across key subgroups, as well as among patients who did or did not achieve pathologic complete response, 5-year follow-up from the randomized phase …

View Post

Optimal Personalization of Therapy In TNBC Necessitates Consistent Biomarker Identification

In In The News by Barbara Jacoby

By: Courtney Flaherty From: onclive.com Identifying targetable mutations using germline testing, next-generation sequencing (NGS), and functional assays are vital for navigating the evolving treatment armamentarium in triple-negative breast cancer (TNBC) and accordingly improving patient outcomes with standard therapies, according to Pooja Advani, MBBS, MD. “After a long time, we are having discussions as to how to sequence medications in TNBC …

View Post

Clinical Challenges: Sequencing in Metastatic TNBC

In In The News by Barbara Jacoby

By: Leah Lawrence, Contributing Writer From: medpagetoday.com As new treatment options continue to emerge for triple-negative breast cancer (TNBC), sequencing of therapy promises to get ever more complicated. TNBC had been estimated to account for about 15% of all breast cancer diagnosesopens in a new tab or window, but that proportion shrank with the new HER2-low designation, which accounts for …